Scientists inhibit cancer gene
Potential therapy for up to 30 percent of human tumors
Attempts to inhibit activated Ras have had limited success until now, but the Huntsman Cancer Institute researchers explain that they have discovered an enzyme that, when inhibited, appears to reduce the incidence of Ras-induced tumors in mice.
Matthew K. Topham, MD, assistant professor of internal medicine at the University of Utah School of Medicine and lead investigator on the study, explains that the research team had originally been testing a group of enzymes that regulate the function of the Ras gene. These enzymes, called diacylglycerol kinases (DGKs), are implicated in tumor growth.
"When we began our investigation using a type of DGK, called DGK iota, we thought that its absence would cause more tumors to develop, as has happened with other DGKs we have tested. This time, though, when we tested mice with an activated Ras gene, but an absent DGK iota gene, the number of tumors was significantly reduced," Topham says. "This result is interesting because it happened when the Ras gene was activated. The implication is that a drug therapy could be developed to reduce tumors caused by Ras without significant side effects."
The researchers used mice that were bred to have a highly "expressed" - meaning highly active - mutant of the Ras oncogene. Such mice were first developed years ago. Prior studies had demonstrated that these mice were very prone to tumors. For the new study, the Huntsman Cancer Institute team deleted the DGK iota gene in these mice and found that they developed few tumors, while mice with an intact DGK iota gene and an activated Ras exhibited significantly more tumors.
Topham says his team will now examine more closely the mechanism behind how DGK iota works to inhibit tumor formation.
Original Publication: Proceedings of the National Academy of Sciences, 2005.
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.